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In 1980, Poiesz et al. (1980) reported for the first time a link between a retrovirus and a human cancer in a patient with cutaneous T-cell lymphoma in the United States. Several years earlier, a clinical entity called adult T-cell leukemia (ATL) was described in Japan by Takatsuki and others (Uchiyama et al., 1977) . Takatsuki and Gallo have recently reviewed elsewhere the original events that led to the findings of ATL (Takatsuki, 2005) and HTLV-1 (human T-cell leukemia virus type 1) (Gallo, 2005) . Contemporaneous research in those early days also provided for the isolation of a retrovirus in Japan named ATLV by Hinuma et al. (1981) and Yoshida et al. (1982) . As ATLV and the virus isolated by Poiesz et al. were found to be identical, a single name, HTLV-1, was adopted.
We are privileged at the quarter century mark after the discovery of HTLV-1 to organize an Oncogene Review issue dedicated to summarizing extant progress in HTLV-1/ATL research. In setting up this issue, we called upon the expertise of a diverse group of colleagues from Japan, Europe, South America, and the United States to review the history, the molecular biology and immunology, the current state of clinical therapy, and the global epidemiology of HTLV-1/ATL. We note that expertise in as well as contributions to these various research areas in HTLV-1 are not limited to those who have generously agreed to write articles; and we regret that format and page limitations prevented us from soliciting the efforts of many other friends and colleagues.
Over the next 14 articles, readers of this issue will be rewarded with detailed narratives of how the disease and the virus were originally discovered, and how we have since approached the study of transmission, gene expression, replication, and pathogenesis of HTLV-1. Among important unanswered questions in HTLV-1/ ATL research are how the virus initiates and maintains transformation of cells, and what are the detailed mechanisms for the virus to engender HTLV-1 associated myelopathy (HAM) and tropical spastic paraparesis (TSP). Naturally, we are disappointed that current clinical treatment for ATL is still woefully inadequate.
We look forward to another Oncogene Review issue reprising the same topic 25 years from now. However, at that juncture, we will be well contented to be interested readers. We fervently hope and expect that over the next quarter century, cure/understanding of HTLV-1/ATL will become fait accompli.
